ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for monitor 브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.

EPIX ESSA Pharma Inc

6.62
0.19 (2.95%)
02 5월(5) 2024 - 마감
15분 지연
기업명 주식 심볼 시장 주식 타입
ESSA Pharma Inc EPIX 나스닥 보통주
  가격 변동 가격 변동 % 주식 가격 최근 거래 시간
0.19 2.95% 6.62 08:03:11
개장가 저가 고가 종가 전일 종가
6.46 6.43 7.13 6.62 6.43
시세 정보 더보기 »

최근 뉴스

일자 시간 출처 제목
09/04/202421:00PRNCAESSA Pharma to Present at the 2024 Bloom Burton & Co...
08/03/202410:13PRNUSESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING..
08/03/202407:18EDGAR2Form 8-K - Current report
06/03/202408:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/02/202421:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/02/202421:01EDGAR2Form 8-K - Current report
13/02/202421:00PRNUSESSA Pharma Provides Corporate Update and Reports Financial..
08/02/202401:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/02/202422:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/02/202422:00PRNCAESSA Pharma to Present at the Oppenheimer 34th Annual..
29/01/202423:15EDGAR2Form 8-K - Current report
27/01/202406:40EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
27/01/202406:27EDGAR2Form DEF 14A - Other definitive proxy statements
26/01/202400:00PRNUSESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386)..
24/01/202406:09EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
18/01/202410:57EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/01/202406:19EDGAR2Form 144 - Report of proposed sale of securities
17/01/202403:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/01/202410:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/01/202406:04EDGAR2Form 144 - Report of proposed sale of securities
12/12/202321:01EDGAR2Form 8-K - Current report
12/12/202321:00EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
12/12/202321:00PRNCAESSA Pharma Provides Corporate Update and Reports Financial..
25/11/202301:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/11/202322:00PRNUSESSA Pharma to Present at the Piper Sandler 35th Annual..
08/11/202322:00PRNCAESSA Pharma to Present at the Jefferies London Healthcare..
07/11/202307:51PRNUSESSA Pharma Enters into At-The-Market Equity Offering Sales..
07/11/202306:57EDGAR2Form 8-K - Current report
27/10/202306:41PRNUSESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386)..
24/10/202305:19EDGAR2Form 8-K - Current report
21/10/202322:00PRNCAESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386)..
11/10/202313:15EDGAR2Form EFFECT - Notice of Effectiveness
04/10/202305:35EDGAR2Form S-3/A - Registration statement under Securities Act of..
20/09/202305:43EDGAR2Form S-3 - Registration statement under Securities Act of..
18/09/202320:05EDGAR2Form 8-K - Current report
18/09/202320:00PRNUSESSA Pharma Announces Initiation of Phase 2 Study Evaluating..
31/08/202320:00PRNCAESSA Pharma Insiders Establish Automatic Securities..
08/08/202320:15EDGAR2Form 8-K - Current report
08/08/202320:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/08/202320:00PRNCAESSA Pharma Provides Corporate Update and Reports Financial..
06/06/202320:00PRNUSESSA Pharma Appoints Lauren Merendino to its Board of..
01/06/202320:00PRNUSESSA Pharma to Present at 2023 Jefferies Healthcare..
11/05/202320:00PRNCAESSA Pharma to Present at JMP Securities Life Sciences..
09/05/202320:00PRNUSESSA Pharma Provides Corporate Update and Reports Financial..

최근 히스토리

Delayed Upgrade Clock